

## Faculty

### Chairs:

**Professor Gregory Lip**  
University of Birmingham  
Birmingham, UK

### Professor Harry Büller

University of Amsterdam  
Amsterdam, The Netherlands

### Speakers:

**Professor Gregory Lip**  
University of Birmingham  
Birmingham, UK

### Professor Manesh Patel

Duke University Medical Center  
Durham, NC, USA

### Professor Harry Büller

University of Amsterdam  
Amsterdam, The Netherlands

### Professor Ajay Kakkar

Barts and the London School  
of Medicine and Dentistry  
London, UK

### Sponsored by Bayer Schering Pharma AG

The marketing authorization for rivaroxaban may vary from country to country. In Sweden, rivaroxaban ('Xarelto') is approved for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.

© Bayer Schering Pharma AG 2010



BHC02290/0810



# Improving Outcomes in Patients at Risk of Thromboembolic Diseases...

## Working toward a clot-free future

Chaired by Gregory Lip and Harry Büller

**Monday 30 August 2010, 18:30–20:00**

Zone A, Room Athens, Stockholmsmässan, Stockholm, Sweden

A Satellite Symposium sponsored by Bayer Schering Pharma AG at the Congress of the European Society of Cardiology Stockholm, Sweden  
28 August–1 September 2010



# Chairmen's Welcome

Dear Colleagues,

We are delighted to invite you to attend our Satellite Symposium at the annual congress of the European Society of Cardiology. It will focus on the current and future management of patients with thromboembolic disease.


Individuals with atrial fibrillation (AF) are at increased risk for a number of clinically significant sequelae, the most frequent and potentially serious of which is stroke resulting from a cardiogenic thrombus. For primary or secondary stroke prevention, patients are currently prescribed either an anticoagulant (vitamin K antagonist) or an antiplatelet regimen depending on their perceived magnitude of risk. The currently established schemes for evaluating stroke risk have proved useful, but are only moderately predictive, in part because they do not recognize a number of known risk factors.

The educational objectives for this session are to provide cardiologists with an understanding of:


- ◆ Recent advances in stroke risk evaluation, including the importance of considering the full clinical picture of patients with AF to ensure that their stroke risk is not underestimated
- ◆ How differences in clinical trial design and the stroke risk profiles of patient populations can be expected to influence both efficacy and safety outcomes in ongoing and future trials
- ◆ The latest data regarding long-term anticoagulation with rivaroxaban in thromboembolic disorders
- ◆ The value of AF Registries and the insights they provide regarding opportunities for improving patient outcomes

We look forward to welcoming you to what promises to be an interesting and informative session and hope that you will join the discussion following the programme.

Kind regards,



Gregory Lip



Harry Büller

# Improving Outcomes in Patients at Risk of Thromboembolic Diseases...

## Working toward a clot-free future

Chaired by Gregory Lip and Harry Büller

**Monday 30 August 2010, 18:30–20:00**

Zone A, Room Athens, Stockholmsmässan, Stockholm, Sweden

A Satellite Symposium sponsored by Bayer Schering Pharma AG at the ESC Congress 2010, 28 August–1 September 2010

**18:30 Welcome and introduction**

Gregory Lip, UK

**18:40 Evaluating stroke and bleeding risk in atrial fibrillation: Where are we now?**

Gregory Lip, UK

**19:00 Impact of risk factors on patient outcomes in AF**

Manesh Patel, USA

**19:20 Evaluating the long-term benefits of anticoagulation in thromboembolic disease**

Harry Büller, The Netherlands

**19:40 Reducing the risk of stroke in patients with AF: What can Registries tell us?**

Ajay Kakkar, UK

**19:55 Summary and close**

Harry Büller, The Netherlands

